All Posts Tagged With: "DEPO"
(BRO) Company News for February 7, 2012 – Corporate Summary
• Pharma company Depomed Inc’s. (NASDAQ:DEPO) shares advanced 5.37% after the company said it would receive royalties from Merck & Co’s (NYSE:MRK)...
(ABT) Company News for January 20, 2011 – Corporate Summary
• Share prices of tech major IBM (NYSE:IBM) rose by 3.35% after the company posted excellent earnings figure on Tuesday night
• Adtran Inc (NASDAQ:ADTN) increased...
(NBIX) Focus Turns To Biotech Next Week
Focus Turns To Biotech Next Week
The week of January 10th is perhaps one of the biggest weeks in the biotechnology industry. Three significant healthcare conferences will take place in San Francisco, headlined by the 29th annual J.P. Morgan Healthcare...
(SNTS) Santarus Earnings Hit by Zegerid Conversion to Generic
Santarus Inc. (SNTS) reported a loss of 32 cents per share in the third quarter, wider than the Zacks Consensus Estimate of a loss of 21 cents and the year-ago earnings of 9 cents. Results were affected by...
(SNTS) Santarus Earnings Beat Expectations on Higher Revenues
Santarus Inc. (SNTS) reported second-quarter earnings of 10 cents per share, well above the Zacks Consensus Estimate of 4 cents and the year-ago earnings of 2 cents. Total revenues, consisting of net product...
(SNTS) Santarus’ Quarterly Earnings Report Strongly Beats Expectations
Santarus, Inc. (SNTS) reported first-quarter earnings of 5 cents per share, well above the Zacks Consensus Estimate of a loss of one cent and the year-ago earnings of 2 cents. Total revenues, consisting...
(SNTS) Less Zegerid, More Glumetza
Yesterday, shares of San Diego specialty pharmaceutical company Santarus (SNTS) sank by 33% on news that a U.S. Federal Court for the District of Delaware has ruled that five patents covering the company’s...
(SNTS) Santarus Suffers Negative Patent Infringement Court Ruling
Santarus, Inc. (SNTS) suffered a major setback recently when a US District Court ruled against the company in a patent infringement case. The U.S. District Court for the District of Delaware ruled that five...
(SNTS) Santarus Beats Earnings Expectations on Higher Revenues
Santarus, Inc. (SNTS) reported fourth quarter earnings of 40 cents per share, doubling the Zacks Consensus Estimate of 20 cents and far above the year-ago earnings of 7 cents. Performance was boosted by higher...
(SNTS) Santarus Recently Downgraded to Neutral
We recently downgraded our recommendation on specialty pharmaceutical company Santarus Inc. (SNTS) to Neutral. Santarus is focused on the acquisition, development, and commercialization of proprietary products...
(DEPO) Depomed, Incorporated – Bull of the Day
We are reiterating our positive rating on Depomed (DEPO). We are very excited about the recent positive phase III data for DM-1796 in PHN and believe the market has yet to factor in the potential that this drug has in terms of delivering milestones and royalties to the company...